Logan Coy Related postsA Phase 1/2 Open-Label, Dose-Escalation Study of Quaratusugene Ozeplasmid in Combination with Osimertinib in Advanced, EGFR-Mutant, Metastatic NSCLC that Progressed after OsimertinibSeptember 11, 2026A Phase 1 Study of IM-1021 in Participants with Advanced MalignanciesSeptember 11, 2026A First-In-Human Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Trial of VERT-002 in Locally Advanced or Metastatic Solid Tumors including NSCLC with MET AlterationsSeptember 11, 2026 Previous postA Phase 1/2 Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Extensive Stage Small Cell Lung Cancer (ES-SCLC)Next postA Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs